Showing results (11-20 of 30) with videos related to

Sort By:
Pageof 3
Plastic and Reconstructive Surgery. Global Open|June 24, 2026
Four Decades of the Anterolateral Thigh Flap: Celebrating a Milestone in Reconstructive MicrosurgeryMarco Marcasciano, Luca Patanè, Fu-Chan Wei, et al.
Hematological Oncology|May 26, 2022
Baseline cluster of differentiation 22 fluorescent intensity correlates with patient outcome after Inotuzumab Ozogamicin treatmentChiara Sartor, Mario Arpinati, Gabriella Chirumbolo, et al.
BMC Cancer|November 17, 2018
Inotuzumab ozogamicin is effective in relapsed/refractory extramedullary B acute lymphoblastic leukemiaLuca Bertamini, Jacopo Nanni, Giovanni Marconi, et al.
Blood Advances|September 17, 2021
An IDO1-related immune gene signature predicts overall survival in acute myeloid leukemiaSimone Ragaini, Sarah Wagner, Giovanni Marconi, et al.
Frontiers in Oncology|October 18, 2021
Case Report: A Novel Activating FLT3 Mutation in Acute Myeloid LeukemiaSamantha Bruno, Lorenza Bandini, Agnese Patuelli, et al.
European Journal of Haematology|February 14, 2022
Impact of infectious comorbidity and overall time of hospitalization in total outpatient management of acute myeloid leukemia patients following venetoclax and hypomethylating agentsCristina Papayannidis, Jacopo Nanni, Gianluca Cristiano, et al.
Biomedicines|April 30, 2021
Pharmacological Inhibition of WIP1 Sensitizes Acute Myeloid Leukemia Cells to the MDM2 Inhibitor Nutlin-3aMaria Chiara Fontana, Jacopo Nanni, Andrea Ghelli Luserna di Rorà, et al.
International Journal of Molecular Sciences|September 28, 2024
Tracking Response and Resistance in Acute Myeloid Leukemia through Single-Cell DNA Sequencing Helps Uncover New Therapeutic TargetsSamantha Bruno, Enrica Borsi, Agnese Patuelli, et al.
Cancer Medicine|December 31, 2021
Assessment of liver stiffness measurement and ultrasound findings change during inotuzumab ozogamicin cycles for relapsed or refractory acute lymphoblastic leukemiaFederico Ravaioli, Giovanni Marconi, Giovanni Martinelli, et al.
Hematological Oncology|January 13, 2026
NPM1 and IDH1/2 Mutations Show Limited Prognostic Impact in Relapsed/Refractory AML: Evidence From the AVALON CohortCalogero Vetro, Irene Azzali, Elisabetta Petracci, et al.
Pageof 3